AU2007212260A1 - Method for treating peripheral arterial disease with zinc finger proteins - Google Patents

Method for treating peripheral arterial disease with zinc finger proteins Download PDF

Info

Publication number
AU2007212260A1
AU2007212260A1 AU2007212260A AU2007212260A AU2007212260A1 AU 2007212260 A1 AU2007212260 A1 AU 2007212260A1 AU 2007212260 A AU2007212260 A AU 2007212260A AU 2007212260 A AU2007212260 A AU 2007212260A AU 2007212260 A1 AU2007212260 A1 AU 2007212260A1
Authority
AU
Australia
Prior art keywords
zinc finger
nucleic acid
finger protein
patient
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007212260A
Other languages
English (en)
Inventor
Brian Annex
Joe Rokovich
Patrice Tremble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangamo Therapeutics Inc
Original Assignee
Sangamo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Therapeutics Inc filed Critical Sangamo Therapeutics Inc
Publication of AU2007212260A1 publication Critical patent/AU2007212260A1/en
Assigned to SANGAMO THERAPEUTICS, INC. reassignment SANGAMO THERAPEUTICS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: SANGAMO BIOSCIENCES, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2007212260A 2006-02-09 2007-02-09 Method for treating peripheral arterial disease with zinc finger proteins Abandoned AU2007212260A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77241706P 2006-02-09 2006-02-09
US60/772,417 2006-02-09
US80323406P 2006-05-25 2006-05-25
US60/803,234 2006-05-25
PCT/US2007/003538 WO2007092609A2 (en) 2006-02-09 2007-02-09 Method for treating peripheral arterial disease with zinc finger proteins

Publications (1)

Publication Number Publication Date
AU2007212260A1 true AU2007212260A1 (en) 2007-08-16

Family

ID=38345833

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007212260A Abandoned AU2007212260A1 (en) 2006-02-09 2007-02-09 Method for treating peripheral arterial disease with zinc finger proteins

Country Status (6)

Country Link
US (1) US20090305977A1 (enExample)
EP (1) EP1993586A4 (enExample)
JP (1) JP2009532326A (enExample)
AU (1) AU2007212260A1 (enExample)
CA (1) CA2641198A1 (enExample)
WO (1) WO2007092609A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6140466A (en) * 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
AU767662B2 (en) * 1998-02-06 2003-11-20 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) * 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
JP2004537260A (ja) * 2000-12-07 2004-12-16 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガータンパク質による血管新生の調節
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7223740B2 (en) * 2001-05-23 2007-05-29 Fornix Biosciences N.V. Vectors for enhanced expression of VEGF for atrial disease treatment
EA009390B1 (ru) * 2003-06-05 2007-12-28 Сентельон Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом
WO2004108883A2 (en) * 2003-06-10 2004-12-16 Toolgen, Inc. Transducible dna-binding proteins
DE602005011943D1 (de) * 2004-04-08 2009-02-05 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen

Also Published As

Publication number Publication date
US20090305977A1 (en) 2009-12-10
WO2007092609A3 (en) 2008-02-21
EP1993586A2 (en) 2008-11-26
EP1993586A4 (en) 2009-10-21
CA2641198A1 (en) 2007-08-16
WO2007092609A2 (en) 2007-08-16
JP2009532326A (ja) 2009-09-10

Similar Documents

Publication Publication Date Title
Makarevich et al. Combined transfer of human VEGF165 and HGF genes renders potent angiogenic effect in ischemic skeletal muscle
AU2010286511B2 (en) SDF-1 delivery for treating ischemic tissue
US20020172663A1 (en) Localized myocardial injection method for treating ischemic myocardium
JP3865632B2 (ja) 心筋症遺伝子治療
US20090038022A1 (en) IGF-1 Novel peptides
CN113564187A (zh) 基于aav的抗血管生成基因递送系统及其用途
US20090305977A1 (en) Method for treating peripheral arterial disease with zinc finger proteins
CN113563430B (zh) 用于治疗眼部疾病的基因递送系统及其应用
CN113480615B (zh) 高视网膜亲和性的新型腺相关病毒衣壳蛋白及其应用
CN113584043B (zh) 用于治疗视网膜疾病和癌症的转基因表达盒
JP2003513942A (ja) インビボ遺伝子送達による心血管疾患を処理するための技術および組成物
JP2004099471A (ja) 心筋梗塞および心不全の治療薬
KR20010108053A (ko) 당뇨병성 허혈성 질환 유전자 치료
Xu et al. Cardiac-specific expression of the hepatocyte growth factor (HGF) under the control of a TnIc promoter confers a heart protective effect after myocardial infarction (MI)
EP1594549B1 (en) Hypoxia inducible vegf plasmid for ischemic disease
CN119013405A (zh) 包含utr的核酸构建体及其应用
Kuroda et al. Effects of viral interleukin 10 introduced by in vivo electroporation on arthrogen-induced arthritis in mice.
WO2022166771A1 (zh) 3'utr的构建方法和应用
CN1389269A (zh) 多肽－脂质体与人血管内皮生长因子基因重组质粒复合物及用途
Malecki et al. In vivo study of angiogenic plasmid preparations—the bicistronic plasmid as a new type of drug for vascular diseases
CN115957301A (zh) 一种促进心梗心肌修复的细胞分泌因子及应用
EA031308B1 (ru) Доставка sdf-1 для лечения ишемизированной ткани
WO2004078192A1 (en) Use of tumor endothelial markers 1, 9 and 17 to promote angiogenesis
WO2004057005A1 (en) Vectors lacking an origin of replication functioning in mammalian cells and expressing growth factors
JP2001335489A (ja) 核酸導入製剤

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
HB Alteration of name in register

Owner name: SANGAMO THERAPEUTICS, INC.

Free format text: FORMER NAME(S): SANGAMO BIOSCIENCES, INC.